FDA Approval Activities for this Drug…

Actos (pioglitazone HCl) Tablets, 15 mg, 30 mg, and 45 mg, Takeda NDA 21-073/S-021 6/11/03 7/8/03 7/8/03 Actos (pioglitazone HCl) Tablets, 15 mg, 30 mg, and 45 mg, Takeda NDA 21-073/S-017 1/17/03 1/23/03 Actos (pioglitazone HCl) Tablets, Takeda NDA 21-073/S16 1/7/02 2/8/02 Actos (pioglitazone HCl) Tablets, 15 mg, 30 mg, and 45 mg, Takeda North America, Inc NDA 21-073/S-018 12/3/02 12/9/02 Actos (pioglitazone) Tablets, Takeda NDA 21-073/S10 7/12/02 7/15/02 7/15/02 Actos (or pioglitazone HCl) oral Tablets, 15 mg, 30 mg, and 45 mg, Takeda NDA 21-073 7/15/99 7/28/99 7/28/99 6/30/00 Actos Indicated: for the improvement of glycemic control in patients with Type 2 diabetes as monotherapy, or in combination with a sulfonylurea, metformin or insulin when diet and the single agent does not result in adequate glycemic control. Actos (pioglitazone HCl) Tablets, Takeda Actos (pioglitazone HCl) Tablets, Takeda, Labeling Revision Actos (pioglitazone HCl) Tablets, Takeda Global, Labeling Revision | Pioglitazone Hydrochloride Tablets, Mylan Pharma, Tentative Approval | Pioglitazone Hydrochloride Tablets, Alphapharm, Tentative Approval

For the latest approval information, please locate this drug using this index.